PROCEPT BioRobotics Files 10-Q/A Amendment

TL;DR

PROCEPT BioRobotics filed a 10-Q/A amendment for Q1 2024. Check for updates.

AI Summary

PROCEPT BioRobotics Corporation filed an amendment (10-Q/A) on June 27, 2024, for the quarterly period ended March 31, 2024. The filing pertains to their operations and financial reporting, with the company incorporated in Delaware and headquartered at 150 Baytech Drive, San Jose, CA.

Why It Matters

This amendment provides updated or corrected information for the quarterly period, which is crucial for investors to have the most accurate financial and operational data.

Risk Assessment

Risk Level: low — This filing is an amendment to a standard quarterly report, indicating routine updates rather than significant new risks.

Key Players & Entities

• PROCEPT BioRobotics Corporation (company) — Registrant
• 150 Baytech Drive, San Jose, CA (location) — Business and Mail Address
• March 31, 2024 (date) — Quarterly period end date
• June 27, 2024 (date) — Filing date of amendment
• Frederic Moll (person) — Member
• Sham Shiblaq (person) — Member
• Alaleh Nouri (person) — Member

FAQ

Key Financial Figures

• $0.00001 — ange on which registered Common stock, $0.00001 par value per share PRCT Nasdaq Global

Filing Documents

• prct-20240331.htm (10-Q/A) — 48KB
• prct-ex311soxcertification.htm (EX-31.1) — 5KB
• prct-ex312soxcertification.htm (EX-31.2) — 5KB
• 0001588978-24-000015.txt ( ) — 453KB
• prct-20240331.xsd (EX-101.SCH) — 3KB
• prct-20240331_def.xml (EX-101.DEF) — 3KB
• prct-20240331_lab.xml (EX-101.LAB) — 110KB
• prct-20240331_pre.xml (EX-101.PRE) — 60KB
• prct-20240331_htm.xml (XML) — 8KB

Other Information

Item 5. Other Information During the quarter ended May 31, 2024, none of the director or officer of the Company informed us of the adoption or termination of a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408 of Regulation S-K), except as follows: On February 29, 2024 , Frederic Moll, M.D. , the Chair of the Company's Board of Directors , terminated a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the "Moll 10b5-1 Plan") under the Exchange Act, for the sale of shares of the Company's common stock. The Moll 10b5-1 Plan was terminated during an open trading window in accordance with the Company's policies regarding transactions in the Company's securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Moll 10b5-1 Plan provided for the potential sale of up to 237,000 shares of the Company's common stock, so long as the market price of the Company's common stock was higher than certain minimum threshold prices specified in the Moll 10b5-1 Plan. The Moll 10b5-1 Plan was to expire on December 31, 2024, or on such earlier date on which all of the trades thereunder had been executed. On March 9, 2024 , Sham Shiblaq , the Company's Chief Commercial Officer , adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the "Shiblaq Rule 10b5-1 Plan") under the Exchange Act, for the sale of shares of the Company's common stock. The Shiblaq Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company's policies regarding transactions in the Company's securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Shiblaq Rule 10b5-1 Plan provides for the potential sale of up to 26,046 shares of the Company's common stock, including upon the exercise of vested stock options for shares of the Company's common stock, so long as the market price of t

Exhibits

Item 6. Exhibits The following exhibits are filed with this Quarterly Report on Form 10-Q/A. Exhibit No. Exhibit Description 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 101 iXBRL (Inline Extensible Business Reporting Language) for the information under Part II, "Item 5, Other Information" of this Amendment No. 1 on Form 10-Q/A. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). F-4

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: June 27, 2024 PROCEPT BIOROBOTICS CORPORATION (Registrant) /s/ Reza Zadno Reza Zadno, Ph.D. President and Chief Executive Officer (principal executive officer) /s/ Kevin Waters Kevin Waters EVP, Chief Financial Officer (principal financial and accounting officer) F-5

View Full Filing

View this 10-Q/A filing on SEC EDGAR